Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Moulédous L[au]:

Mitochondria in Developmental and Adult Neurogenesis. Arrázola MS et al. Neurotox Res. (2019)

Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation. Rekik K et al. Neuropharmacology. (2017)

Roles of the ubiquitin proteasome system in the effects of drugs of abuse. Massaly N et al. Front Mol Neurosci. (2014)

Search results

Items: 47

1.

Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists.

Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S.

Sci Signal. 2019 Mar 26;12(574). pii: eaau8072. doi: 10.1126/scisignal.aau8072.

PMID:
30914485
2.

Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse.

Coutens B, Mouledous L, Stella M, Rampon C, Lapeyre-Mestre M, Roussin A, Guiard BP, Jouanjus E.

Psychopharmacology (Berl). 2019 Jul;236(7):2069-2082. doi: 10.1007/s00213-019-05198-z. Epub 2019 Mar 16.

PMID:
30879119
3.

Development and characterization of sphingosine 1-phosphate receptor 1 monoclonal antibody suitable for cell imaging and biochemical studies of endogenous receptors.

Talmont F, Moulédous L, Baranger M, Gomez-Brouchet A, Zajac JM, Deffaud C, Cuvillier O, Hatzoglou A.

PLoS One. 2019 Mar 7;14(3):e0213203. doi: 10.1371/journal.pone.0213203. eCollection 2019.

4.

The Nociceptin/Orphanin FQ System and the Regulation of Memory.

Moulédous L.

Handb Exp Pharmacol. 2019;254:259-278. doi: 10.1007/164_2018_185.

PMID:
30430261
5.

Mitochondria in Developmental and Adult Neurogenesis.

Arrázola MS, Andraini T, Szelechowski M, Mouledous L, Arnauné-Pelloquin L, Davezac N, Belenguer P, Rampon C, Miquel MC.

Neurotox Res. 2019 Aug;36(2):257-267. doi: 10.1007/s12640-018-9942-y. Epub 2018 Sep 13.

PMID:
30215161
6.

Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.

Rekik K, Faria Da Silva R, Colom M, Pacifico S, Zaveri NT, Calo' G, Rampon C, Frances B, Mouledous L.

Neuropharmacology. 2017 Oct;125:39-49. doi: 10.1016/j.neuropharm.2017.07.006. Epub 2017 Jul 10.

PMID:
28705439
7.

Phosphoproteomic analysis of the mouse brain mu-opioid (MOP) receptor.

Moulédous L, Froment C, Burlet-Schiltz O, Schulz S, Mollereau C.

FEBS Lett. 2015 Aug 19;589(18):2401-8. doi: 10.1016/j.febslet.2015.07.025. Epub 2015 Jul 29.

8.

Beneficial effects of levobupivacaine regional anaesthesia on postoperative opioid induced hyperalgesia in diabetic mice.

Gomez-Brouchet A, Blaes N, Mouledous L, Fourcade O, Tack I, Francès B, Girolami JP, Minville V.

J Transl Med. 2015 Jul 2;13:208. doi: 10.1186/s12967-015-0575-0.

9.

Roles of the ubiquitin proteasome system in the effects of drugs of abuse.

Massaly N, Francès B, Moulédous L.

Front Mol Neurosci. 2015 Jan 6;7:99. doi: 10.3389/fnmol.2014.00099. eCollection 2014. Review.

10.

Identification and functional characterization of the phosphorylation sites of the neuropeptide FF2 receptor.

Bray L, Froment C, Pardo P, Candotto C, Burlet-Schiltz O, Zajac JM, Mollereau C, Moulédous L.

J Biol Chem. 2014 Dec 5;289(49):33754-66. doi: 10.1074/jbc.M114.612614. Epub 2014 Oct 17.

11.

Heterologous regulation of Mu-opioid (MOP) receptor mobility in the membrane of SH-SY5Y cells.

Carayon K, Moulédous L, Combedazou A, Mazères S, Haanappel E, Salomé L, Mollereau C.

J Biol Chem. 2014 Oct 10;289(41):28697-706. doi: 10.1074/jbc.M114.588558. Epub 2014 Sep 2.

12.

Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5.

Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S.

Biol Psychiatry. 2014 Nov 15;76(10):767-74. doi: 10.1016/j.biopsych.2014.01.021. Epub 2014 Feb 3.

13.

A high-affinity, radioiodinatable neuropeptide FF analogue incorporating a photolabile p-(4-hydroxybenzoyl)phenylalanine.

Bray L, Moulédous L, Tafani JA, Germanier M, Zajac JM.

Anal Biochem. 2014 May 15;453:50-4. doi: 10.1016/j.ab.2014.02.029. Epub 2014 Mar 5.

PMID:
24613258
14.

Solubilization and reconstitution of the mu-opioid receptor expressed in human neuronal SH-SY5Y and CHO cells.

Talmont F, Moulédous L, Mollereau C, Zajac JM.

Peptides. 2014 May;55:79-84. doi: 10.1016/j.peptides.2014.02.009. Epub 2014 Feb 25.

PMID:
24582609
15.

Evaluation of commercial antibodies against human sphingosine-1-phosphate receptor 1.

Talmont F, Moulédous L.

Naunyn Schmiedebergs Arch Pharmacol. 2014 May;387(5):427-31. doi: 10.1007/s00210-014-0957-5. Epub 2014 Jan 24.

PMID:
24458374
16.

Role of kinin B2 receptors in opioid-induced hyperalgesia in inflammatory pain in mice.

Grastilleur S, Mouledous L, Bedel J, Etcheverry J, Bader M, Girolami JP, Fourcade O, Frances B, Minville V.

Biol Chem. 2013 Mar;394(3):361-8. doi: 10.1515/hsz-2012-0305.

PMID:
23324378
17.

Involvement of protein degradation by the ubiquitin proteasome system in opiate addictive behaviors.

Massaly N, Dahan L, Baudonnat M, Hovnanian C, Rekik K, Solinas M, David V, Pech S, Zajac JM, Roullet P, Mouledous L, Frances B.

Neuropsychopharmacology. 2013 Mar;38(4):596-604. doi: 10.1038/npp.2012.217. Epub 2012 Nov 21.

18.

Denatured G-protein coupled receptors as immunogens to generate highly specific antibodies.

Talmont F, Moulédous L, Boué J, Mollereau C, Dietrich G.

PLoS One. 2012;7(9):e46348. doi: 10.1371/journal.pone.0046348. Epub 2012 Sep 27.

19.

GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.

Moulédous L, Froment C, Dauvillier S, Burlet-Schiltz O, Zajac JM, Mollereau C.

J Biol Chem. 2012 Apr 13;287(16):12736-49. doi: 10.1074/jbc.M111.314617. Epub 2012 Feb 28.

20.

Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.

Elhabazi K, Trigo JM, Mollereau C, Moulédous L, Zajac JM, Bihel F, Schmitt M, Bourguignon JJ, Meziane H, Petit-demoulière B, Bockel F, Maldonado R, Simonin F.

Br J Pharmacol. 2012 Jan;165(2):424-35. doi: 10.1111/j.1476-5381.2011.01563.x.

21.

Central apelin controls glucose homeostasis via a nitric oxide-dependent pathway in mice.

Duparc T, Colom A, Cani PD, Massaly N, Rastrelli S, Drougard A, Le Gonidec S, Moulédous L, Frances B, Leclercq I, Llorens-Cortes C, Pospisilik JA, Delzenne NM, Valet P, Castan-Laurell I, Knauf C.

Antioxid Redox Signal. 2011 Sep 15;15(6):1477-96. doi: 10.1089/ars.2010.3454. Epub 2011 May 25.

PMID:
21395477
22.

Opioid-modulating properties of the neuropeptide FF system.

Moulédous L, Mollereau C, Zajac JM.

Biofactors. 2010 Nov-Dec;36(6):423-9. doi: 10.1002/biof.116. Epub 2010 Aug 27. Review.

PMID:
20803521
23.

Opposite control of body temperature by NPFF1 and NPFF2 receptors in mice.

Moulédous L, Barthas F, Zajac JM.

Neuropeptides. 2010 Oct;44(5):453-6. doi: 10.1016/j.npep.2010.05.003. Epub 2010 Jun 15.

PMID:
20554321
24.

Modulation of basal and morphine-induced neuronal activity by a NPFF(2) selective agonist measured by c-Fos mapping of the mouse brain.

Moulédous L, Frances B, Zajac JM.

Synapse. 2010 Sep;64(9):672-81. doi: 10.1002/syn.20774.

PMID:
20336629
25.

Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins.

Kersanté F, Moulédous L, Zajac JM, Mollereau C.

Neurochem Int. 2010 May-Jun;56(6-7):768-73. doi: 10.1016/j.neuint.2010.02.014. Epub 2010 Mar 6.

PMID:
20211672
26.

Pharmacological characterization of the mouse NPFF2 receptor.

Talmont F, Moulédous L, Piedra-Garcia L, Schmitt M, Bihel F, Bourguignon JJ, Zajac JM, Mollereau C.

Peptides. 2010 Feb;31(2):215-20. doi: 10.1016/j.peptides.2009.11.020. Epub 2009 Nov 26.

PMID:
19944730
27.

Central locomotor and cognitive effects of a NPFF receptor agonist in mouse.

Betourne A, Marty V, Ceccom J, Halley H, Lassalle JM, Zajac JM, Frances B, Mouledous L.

Peptides. 2010 Feb;31(2):221-6. doi: 10.1016/j.peptides.2009.11.009. Epub 2009 Nov 18.

PMID:
19931330
28.

Description of the low-affinity interaction between nociceptin and the second extracellular loop of its receptor by fluorescence and NMR spectroscopies.

Vincent B, Mouledous L, Bes B, Mazarguil H, Meunier JC, Milon A, Demange P.

J Pept Sci. 2008 Nov;14(11):1183-94. doi: 10.1002/psc.1057.

PMID:
18683278
29.

Protein degradation, as with protein synthesis, is required during not only long-term spatial memory consolidation but also reconsolidation.

Artinian J, McGauran AM, De Jaeger X, Mouledous L, Frances B, Roullet P.

Eur J Neurosci. 2008 Jun;27(11):3009-19. doi: 10.1111/j.1460-9568.2008.06262.x.

PMID:
18588539
30.

Neuropeptide FF-sensitive confinement of mu opioid receptor does not involve lipid rafts in SH-SY5Y cells.

Moulédous L, Merker S, Neasta J, Roux B, Zajac JM, Mollereau C.

Biochem Biophys Res Commun. 2008 Aug 15;373(1):80-4. doi: 10.1016/j.bbrc.2008.05.174. Epub 2008 Jun 9.

31.
32.

Effect of long-term exposure of SH-SY5Y cells to morphine: a whole cell proteomic analysis.

Neasta J, Uttenweiler-Joseph S, Chaoui K, Monsarrat B, Meunier JC, Moulédous L.

Proteome Sci. 2006 Dec 21;4:23.

33.

Long-term morphine treatment enhances proteasome-dependent degradation of G beta in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylate cyclase sensitization.

Moulédous L, Neasta J, Uttenweiler-Joseph S, Stella A, Matondo M, Corbani M, Monsarrat B, Meunier JC.

Mol Pharmacol. 2005 Aug;68(2):467-76. Epub 2005 May 18.

PMID:
15901846
35.

Navigated laser capture microdissection as an alternative to direct histological staining for proteomic analysis of brain samples.

Moulédous L, Hunt S, Harcourt R, Harry J, Williams KL, Gutstein HB.

Proteomics. 2003 May;3(5):610-5.

PMID:
12748941
36.

Gene arrays and proteomics. A primer.

Moulédous L, Gutstein HB.

Methods Mol Med. 2003;84:141-54. No abstract available.

PMID:
12703322
37.

Proteomic analysis of immunostained, laser-capture microdissected brain samples.

Moulédous L, Hunt S, Harcourt R, Harry JL, Williams KL, Gutstein HB.

Electrophoresis. 2003 Jan;24(1-2):296-302.

PMID:
12652601
38.

Nitroglycerin inhibits the development of morphine tolerance and dependence in rats.

Cha EY, Moulédous L, Harris JR, Weech MA, Gutstein HB.

Pharmacol Biochem Behav. 2003 Feb;74(3):551-7.

PMID:
12543218
39.

Lack of compatibility of histological staining methods with proteomic analysis of laser-capture microdissected brain samples.

Mouledous L, Hunt S, Harcourt R, Harry JL, Williams KL, Gutstein HB.

J Biomol Tech. 2002 Dec;13(4):258-64.

40.

Tissue distribution of the opioid receptor-like (ORL1) receptor.

Mollereau C, Mouledous L.

Peptides. 2000 Jul;21(7):907-17. Review.

PMID:
10998524
41.

The nociceptin (ORL1) receptor: molecular cloning and functional architecture.

Meunier J, Mouledous L, Topham CM.

Peptides. 2000 Jul;21(7):893-900. Review.

PMID:
10998522
43.
45.

Characterization of a new radioiodinated probe for the alpha2C adrenoceptor in the mouse brain.

Dossin O, Moulédous L, Baudry X, Tafani JA, Mazarguil H, Zajac JM.

Neurochem Int. 2000 Jan;36(1):7-18.

PMID:
10566954
46.

Molecular modelling of the ORL1 receptor and its complex with nociceptin.

Topham CM, Moulédous L, Poda G, Maigret B, Meunier JC.

Protein Eng. 1998 Dec;11(12):1163-79. Erratum in: Protein Eng 1999 Oct;12(10):893.

PMID:
9930666
47.

Distinct mechanisms for activation of the opioid receptor-like 1 and kappa-opioid receptors by nociceptin and dynorphin A.

Mollereau C, Mouledous L, Lapalu S, Cambois G, Moisand C, Butour JL, Meunier JC.

Mol Pharmacol. 1999 Feb;55(2):324-31.

PMID:
9927625

Supplemental Content

Loading ...
Support Center